HALO

Halozyme Therapeutics (HALO), classified in the Health Care sector, has attracted modest congressional trading interest in public disclosures, with three members — Gil Cisneros, Daniel Goldman, and Josh Gottheimer — collectively filing four trades between December 2022 and March 2026. The balance skews toward selling, with three sales against one purchase, and no bipartisan co-trading clusters are recorded for this ticker. Three executive-branch officials have separately disclosed five transactions in the same security, though the closest congressional and executive purchases in the record fall 252 days apart, outside the 90-day proximity window used to flag temporal overlap. The overall congressional footprint in this name is thin, and the buy/sell ratio reflects net disposition across the disclosure period.